Table 3.
Characteristics of Patients in the Alirocumab Group Who Achieved Consecutive LDL-C Levels <15 mg/dL and Propensity Score–Matched Patients From the Placebo Group
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.